|
"bianchini g"的相關文件
顯示項目 1-3 / 3 (共1頁)
1
每頁顯示[10|25|50]項目
| 國立成功大學 |
2023 |
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|
Hurvitz, S.A.;Hegg, R.;Chung, W.-P.;Im, S.-A.;Jacot, W.;Ganju, V.;Chiu, J.W.Y.;Xu, B.;Hamilton, E.;Madhusudan, S.;Iwata, H.;Altintas, S.;Henning, J.-W.;Curigliano, G.;Perez-Garcia, J.M.;Kim, S.-B.;Petry, V.;Huang, C.-S.;Li, W.;Frenel, J.-S.;Antolin, S.;Yeo, W.;Bianchini, G.;Loi, S.;Tsurutani, J.;Egorov, A.;Liu, Y.;Cathcart, J.;Ashfaque, S.;Cort�s, J. |
| 臺大學術典藏 |
2022-04-15T02:35:15Z |
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
|
Gianni, L; CHIUN-SHENG HUANG; Egle, D; Bermejo, B; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Bianchini, G; Russo, S; Ciruelos, E M; Greil, R; Semiglazov, V; Colleoni, M; Kelly, C; Mariani, G; Del Mastro, L; Maffeis, I; Valagussa, P; Viale, G |
| 中國醫藥大學 |
2010 |
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated activation of Src and inactivation of PTEN
|
(Liang K,); (Esteva FJ); (Albarracin C); (Stemke-Hale K); (Lu Y); (Bianchini G); (Yang CY); (Li Y,); (Li X); (Chen CT); (Mills GB); (Hortobagyi GN); (Mendelsohn J); 洪明奇(Mien-Chie Hung); (Fan Z.)* |
顯示項目 1-3 / 3 (共1頁)
1
每頁顯示[10|25|50]項目
|
